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2 ASAI ET ALstudies from the Canadian, American (n5 2), Australian,
German, and Dutch (n5 2) populations.
Results: An SNP near integrin a6 (ITGA6) reached genome-
wide significance with PA (P5 1.803 1028), whereas SNPs
associated with Src kinase–associated phosphoprotein 1
(SKAP1), matrix metallopeptidase 12 (MMP12)/MMP13, catenin
a3 (CTNNA3), rho GTPase–activating protein 24 (ARHGAP24),
angiopoietin 4 (ANGPT4), chromosome 11 open reading frame
(C11orf30/EMSY), and exocyst complex component 4 (EXOC4)
reached a threshold suggestive of association (P <_ 1.493 1026).
In the meta-analysis of PA, loci in or near ITGA6, ANGPT4,
MMP12/MMP13, C11orf30, and EXOC4 were significant
(P <_ 1.493 1026). When a phenotype of any food allergy was
used for meta-analysis, the C11orf30 locus reached genome-wide
significance (P5 7.503 10211), whereas SNPs associated with
ITGA6, ANGPT4, MMP12/MMP13, and EXOC4 and additional
C11orf30 SNPs were suggestive (P <_ 1.493 1026). Functional
annotation indicated that SKAP1 regulates expression of CBX1,
which colocalizes with the EMSY protein coded by C11orf30.
Conclusion: This study identifies multiple novel loci as risk
factors for PA and food allergy and establishes C11orf30 as a
risk locus for both PA and food allergy. Multiple genes
(C11orf30/EMSY, SKAP1, and CTNNA3) identified by this study
are involved in epigenetic regulation of gene expression. (J
Allergy Clin Immunol 2017;nnn:nnn-nnn.)
Key words: Peanut allergy, food allergy, genome-wide association
study, meta-analysis, EMSY, C11orf30, epigenetics
Peanut allergy (PA) is a main cause of anaphylaxis in North
America.1,2 In Canada the prevalence of PA is 1% overall, with a
prevalence of 2.2% in children.2 The self-reported prevalence of
tree nut allergy and PA in the United States was 2.1% in children,1
whereas 3% of infants in an Australian study had a positive food
challenge result to peanut.3 PA is highly heritable, with a concor-
dance rate of 64% in monozygotic twins compared with 7% in
dizygotic twins.4 Family studies have found the risk of PA in
subjects with a sibling with PA to be significantly greater than
in the general population, with odds ratios (ORs) ranging from
6.7 to 13.5.5,6
The pathogenesis of PA involves both genetics and the
environment. Involvement of environmental exposures is
supported by (1) findings that early oral exposure to peanut leads
to development of tolerance,7,8 (2) differences in PA prevalence
internationally,9-11 and (3) the rapid increase in disease
prevalence reported in some studies that cannot be explained by
genetic changes.1
Previous genetic work has found risk factors for PA in the
innate and adaptive immune pathways, including HLA,12-15
CD14,16 IL9,17 and filaggrin (FLG).18,19 Recently, genome-
wide association studies (GWASs) of food allergy identified
associations between PA and the HLA region.20,21 We have
previously identified HLA and FLG associations with PA in a
well-characterized group of Canadian patients with PA from the
Canadian Peanut Allergy Registry (CanPAR).15,18,19 As a
follow-up to this work, we conducted a GWAS of PA,22 along
with a meta-analysis of results from the previously published
GWASs20,21 and other studies of food allergy. HLA variants
were identified as significant risk factors for PA in the CanPAR
GWAS (rs1049213, P5 1.823 10211) and in a meta-analysis
(rs1063347, P5 3.673 10223), as reported in a separatepublication, in which we narrowed the locus to HLA-DQB1 and
showed that its relationship to PA is independent of asthma.22
Here we present novel non-HLA loci identified in a GWAS and
meta-analysis in an additional 6 populations.
METHODS
Clinical characteristics
Inclusion criteria for CanPAR cases are found in Table E1 in this article’s
Online Repository at www.jacionline.org.19GWAS
Salivary DNA was isolated from patients with PA in the CanPAR study.
Hyper-control subjects were self-reported white subjects from the
Busselton Health Study in Australia with no history of asthma, airway
hyperresponsiveness, atopy, eczema, allergic rhinitis, or food allergy who had
blood-derived DNA and assessment by usingmethacholine challenge and skin
prick tests.23 Genotyping of 1974 subjects (987 cases and 987 control subjects)
was conducted on the Illumina Omni 2.5M1Exome 8v1.1 chip (Genome
Quebec Innovation Centre, Montreal, Quebec, Canada). Quality control
(QC), including batch effects, single nucleotide polymorphisms (SNPs), and
sample quality, are described in Fig E1 in this article’s Online Repository at
www.jacionline.org. A total of more than 7.8 million SNPs (1,388,588
genotyped and 6,441,607 imputed) and 1,776 subjects (850 cases and 926
control subjects) passed QC (see Fig E2 in this article’s Online Repository
at www.jacionline.org). Details on imputation are presented in the Methods
section in this article’s Online Repository at www.jacionline.org.
Two analyses were performed (related and unrelated) because examination
of alleles determined to be identical by using state and KING24 kinship
coefficients identified related cases (siblings) and control subjects (first- to
third-degree relatives). PC-AiR25 and KING24 (KING1.4; http://people.
virginia.edu/;wc9c/KING/) were used to estimate principal components
and kinship coefficients for the related analysis. Association analyses were
conducted with Stata software,26 with sandwich estimation to model the
clustering of family genotypes with the addition of a family group identifier,
10 principal components to account for population stratification, and plate
numbers to account for plate effects.
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with PLINK (version 1.07).27 To make the sample unrelated, 160 subjects
were excluded (14 cases and 146 control subjects); the youngest subject in
each family was retained. The unrelated analysis was performed with 834
cases and 781 control subjects (n5 1615; see Fig E2, B).
The analysis including related subjects is our primary analysis because it
has the largest sample size and greatest power. Rank order and OR differences
were evaluated between related and unrelated analyses. All subsequent
analyses, including conditioning, were conducted by using the related
analysis. A P value of 3.60 3 1028 was considered the threshold for
genome-wide significance (Bonferroni correction), with 1.49 3 1026 being
suggestive evidence for association. We chose 1.49 3 1026 as our threshold
based on significance levels presented in 2 previously published PA GWAS
studies.20,21Conditioning on HLA
After identification of multiple SNPs in the HLA region,22 we conditioned
on the top genotyped SNP (rs3134976) to investigate independence of signals
from the rest of the genome and to determine the contribution of HLA associ-
ations to deviation from the expected line observed in the quantile-quantile
plots (Fig 1).Meta-analysis
A meta-analysis was conducted by using 2 phenotypes (PA and food
allergy), including previously published PA GWAS results20,21 and unpub-
lished data. The CanPAR study and 6 additional studies were included in
the meta-analysis: 2 American studies (the Chicago FoodAllergy [CFA] study
[n5 2,197; 316 PA cases]20 and the Genetic Epidemiology Research on Ag-
ing [GERA] cohort [n5 29,053; 5,108 self-reported food allergy]),28 the
AustralianHealthNuts study (n5 221; 73 patients with PA),21 and theGerman
Understanding FoodAllergy (UFA) study (n5 2,592; 205 patients with PA),21
which contributed 21 previously published SNPs. Genotyping for SNPs was
conducted in 2 Dutch studies: IDEAL and GENEVA (n5 512; 138 patients
with PA). Both IDEAL and GENEVA include cases with general food al-
lergy.29 See Table E2 in this article’s Online Repository at www.jacionline.
org for full study and phenotype descriptions. The meta-analysis for PA
included 1,582 patients with PA and 5,446 control subjects, with more than
half of the patients and control subjects coming from the CanPAR study.
Because the GERA cohort used self-reported food allergy phenotypes with
no additional diagnostic testing or history, the meta-analysis was completed
both with and without GERA data to evaluate the sensitivity of the meta-
analysis results to stringent food allergy phenotyping. The meta-analysis for
food allergy included 7,267 patients with food allergy and 29,084 control sub-
jects, with inclusion of GERA data.
Fixed- and random-effects models evaluate heterogeneity but require point
estimates and SEs. Because the CFA study provided P values and sample sizes
only, for meta-analyses, P values were obtained by using the Stouffer
weighted z score, which requires consistency in the direction of effects (for ac-
curate P value estimation), and we were able to confirm that the direction of
effect is the same for the CFA study because the investigators provided us
with the case/control allele frequencies, which are consistent with the CanPAR
associations.Identification of expression quantitative trait loci
The Genotype-Tissue Expression (gtexportal.org)30 database was queried
for novel regions.RESULTS
GWAS
SNPs inHLA22 and an imputed SNP on chromosome 2 close to
integrin a6 (ITGA6; rs115218289, P5 1.803 1028; Fig 1 and
Table I and see Table E3 in this article’s Online Repository atwww.jacionline.org) reached genome-wide significance. Several
SNPs with suggestive evidence for association were detected in
novel loci (Table I and see Table E3), including multiple SNPs
located in Src kinase–associated phosphoprotein 1 (SKAP1;
chromosome 17), 1 located between matrix metallopeptidase 12
(MMP12) and MMP13 (rs144897250, chromosome 11;
P5 2.903 1027), multiple SNPs within catenin a3 (CTNNA3;
chromosome 10), rs744597 near rho GTPase–activating
protein 24 (ARHGAP24; chromosome 4, P5 3.983 1027),
rs523865 in angiopoietin 4 (ANGPT4; chromosome 20,
P5 4.423 1027), multiple SNPs near the chromosome 11
open reading frame (C11orf30; chromosome 11, also known as
EMSY), and rs78048444, which is located in a region between
coiled-coil-helix-coiled-coil-helix domain containing 3
(CHCHD3) and exocyst complex component 4 (EXOC4;
chromosome 7, P5 5.443 1027).
No significant difference in ORs for SNPs was noted between
the unrelated and related analyses (Table I). For 2 imputed SNPs
(rs115218289 and rs144897250) with low (approximately 2%)
minor allele frequency (MAF), there were differences in the
rank order between the related and unrelated analyses (see
Table E3 in this article’s Online Repository at www.jacionline.
org), likely because of the low MAF.Conditioning
After conditioning on the top genotypedHLA SNP (rs3134976,
Fig 2), deviation observed in the quantile-quantile plot was
largely resolved (Figs 1, A, and 2, A); residual deviation is
primarily due to the number of SNPs supporting SKAP1,
CTNNA3, and C11orf30/EMSY associations. Conditioning
identified 16 additional SNPs near SKAP1 and CTNNA3
(rs139902172, see Table E4 in this article’s Online Repository
at www.jacionline.org).Meta-analysis for PA
We identified 85 SNPs in common between the CanPAR study
and 1 or more of the previously reported PAGWASs.20,21 The top
novel SNP identified in the meta-analysis for PA was
rs115218289, which was located near ITGA6 and did not reach
genome-wide significance but met the threshold suggestive for
significance (P5 9.163 1028; Table II and see Table E5 and
full results in Table E6 in this article’s Online Repository at
www.jacionline.org). Loci in ANGPT4 (rs523865,
P5 1.543 1027) and intragenic SNPs (rs144897250,
P5 2.943 1027) near MMP12/MMP13, C11orf30 (rs7936434,
P5 3.133 1027), and EXOC4 (rs78048444, P5 3.733 1027)
were suggestive of significance (P <_ 1.493 1026) in a meta-
analysis for the PA phenotype.Meta-analysis of food allergy
By using the phenotype of ‘‘any food allergy’’ in all 6
populations, both with and without GERA data, the top SNP
identified in meta-analysis was rs7936434 near C11orf30
(P5 1.983 1028 and P5 7.503 10211 with and without
GERA data, respectively; Table II and see Table E5). The SNPs
associated with ITGA6, ANGPT4, and MMP12/MMP13 were
suggestive of significance (P <_ 1.493 1026) in a meta-analysis
for food allergy but only if GERA data were not included
FIG 1. Quantile-quantile andManhattan plots of related and unrelated analyses.A,Quantile-quantile plot of
the expected distribution of test statistics (x-axis) versus observed P values (y-axis) for related (left) and
unrelated (right) analyses. B,Manhattan plot: SNPs in 850 patients with PA and 926 hyper-control subjects
for the related (upper) and unrelated (lower) analyses. The x-axis denotes the genomic location, and the
y-axis denotes the association level. The solid line indicates the threshold for genome-wide significance
(P <_ 3.603 1028), and the dashed line indicates the suggestive association significance threshold (P <_ 1.49
3 1026).
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TABLE I. Most significant SNPs from 10 genomic regions identified in the CanPAR GWAS listed by order of significance*
SNP Chromosome Position Allele MAF
Source
of SNPs
Related analysis (850 cases and
926 control subjects)
Unrelated analysis (834 cases and
781 control subjects)
P valuey Gene/nearest geneOR LCI UCI P value OR LCI UCI P value
rs115218289 2 173265750 A/C 0.02 Imputed 0.18 0.10 0.32 1.803 1028 0.20 0.09 0.46 1.393 1024 8.043 1021 (298 kb)DLX2 j
(26 kb)ITGA6
rs72827854 17 46460525 T/C 0.09 Imputed 2.16 1.61 2.90 2.603 1027 2.08 1.50 2.87 9.003 1026 8.583 1021 SKAP1
rs144897250 11 102750264 A/C 0.02 Imputed 6.20 3.09 12.45 2.903 1027 6.72 2.72 16.64 3.793 1025 8.903 1021 (5 kb)MMP12 j
(63 kb)MMP13
rs7475217 10 68444013 T/C 0.38 Genotyped 1.64 1.35 1.98 3.583 1027 1.56 1.28 1.90 9.193 1026 7.373 1021 CTNNA3
rs744597 4 86337028 A/G 0.40 Genotyped 0.61 0.50 0.74 3.983 1027 0.63 0.52 0.77 3.913 1026 8.013 1021 ARHGAP24
rs523865 20 894881 C/T 0.23 Genotyped 0.57 0.46 0.71 4.423 1027 0.57 0.45 0.71 1.193 1026 9.493 1021 ANGPT4
rs7936434 11 76293805 C/G 0.49 Imputed 1.58 1.32 1.90 5.173 1027 1.58 1.31 1.91 2.733 1026 9.853 1021 (30 kb)C11orf30 j
(43 kb)
LOC101928813
rs78048444 7 132832218 C/T 0.02 Genotyped 0.22 0.12 0.39 5.443 1027 0.23 0.11 0.46 4.573 1025 9.353 1021 (65 kb)CHCHD3 j
(106 kb)
EXOC4
rs56151068 17 46381431 T/C 0.10 Imputed 2.06 1.54 2.76 9.583 1027 1.97 1.44 2.70 2.343 1025 8.393 1021 SKAP1;
LOC101927148
rs139462954 17 46523678 A/AC 0.09 Imputed 2.06 1.54 2.76 1.233 1026 1.97 1.43 2.71 2.923 1025 8.373 1021 LOC101927166
Allele, Minor allele/major allele; LCI, lower 95% CI; UCI, upper 95% CI.
*The nearest gene was used to determine genomic location.
Comparing related and unrelated analyses ORs.
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SKAP1, and CTNNA3 were not suggestive of significance for
food allergy.Identification of expression quantitative trait loci
Many SNPs identified near SKAP1 by the CanPAR study were
expression quantitative trait loci (eQTLs) regulating expression
of 2 genes, sorting nexin 1 (SNX11) and chromobox protein
homolog 1 (CBX1), in numerous tissues (sun-exposed skin, whole
blood, transformed fibroblasts, testis, colon, and thyroid). Results
are presented for tissues relevant to PA and food allergy (sun-
exposed skin, whole blood, and transformed fibroblasts) with a
P value of less than 1.03 1026 (Table III and see Table E7 in
this article’s Online Repository at www.jacionline.org). Little is
known about SNX11; it belongs to a family of retrograde transport
molecules,31 and its protein is involved in targeting cell-surface
molecules to the lysosome.32 CBX1 is a member of the highly
conserved heterochromatin protein family that binds to histones
through methylated lysine residues, mediating gene silencing
and alternative splicing.33,34 It is believed that CBX1 can play
an important role in epigenetic regulation and gene expression.DISCUSSION
This study identifies several novel loci for PA and food allergy.
The effect sizes for the identified loci are large, with ORs ranging
from 0.18 to 0.22 and 1.57 to 6.20; these effect sizes are
particularly impressive for a complex disease and a small
GWAS. The most significant novel PA locus from the CanPAR
GWAS and PA meta-analysis was rs115218289, which is located
in ITGA6. This was an imputed SNP with lowMAF (0.021), with
no directly genotyped SNPs supporting the association (Fig 1, A).
A second imputed SNP near MMP12/MMP13 also had a low
MAF (0.02). Although significant or suggestive of significance
in both the PA GWAS and meta-analyses, the rank order of these
2 loci changed between the related and unrelated analyses, but nosignificant changes in the ORs were observed. SKAP1, CTNNA3,
andARHGAP24were identified as suggestive for association with
PA in the CanPAR GWAS but were not suggestive for association
with PA in the meta-analysis. This is likely due to the small
sample size and limited number of contributing studies, as
evidenced by the minimal change in P values for these loci in
CanPAR GWAS data compared with the meta-analysis.
Loci in ANGPT4, C11orf30, and EXOC4 were suggestive of
significance in a meta-analysis for the phenotype of PA but did
not reach genome-wide significance, likely because of small PA
sample sizes and heterogeneity in study designs (case-control
vs family-based studies) and ascertainment criteria. Phenotype
definitions of both cases and control subjects differed in each
population: cases were defined by food challenge (IDEAL and
GENEVA), food challenge and history with confirmatory testing
(CanPAR, CFA, and HealthNuts studies), or self-report (GERA
cohort), whereas control subjects ranged from hyper-control
subjects (CanPAR study), control subjects without food allergy
(IDEAL and GENEVA), control subjects without positive skin
prick test responses to foods (HealthNuts study), population-
based control subjects (CanPAR study, GERA cohort, and UFA
study), and subjects with other food allergies (CFA study).
Ethnicity was diverse across studies, with variable analytic
methods used to control for it; age also differed because of the
use of population-based control subjects. The Busselton cohort
is a longitudinal data set, use of which is required for hyper-
control subjects because they must have negative results for
allergic phenotypes and inherently be older to ensure they will
not have eczema, asthma, or other allergic phenotypes. Our
efforts to evaluate effect sizes across studies and populations
were additionally hindered by differences in GWAS chip and
imputation reference panels. C11orf30 is a prime example: it
was identified in the CanPAR GWAS with PA, but it only reaches
genome-wide significance (P5 7.503 10211) in the meta-
analysis of food allergy. This is likely due to the small PA sample
sizes in the other studies. This finding has important implications
for other loci identified in the CanPAR GWAS: the lack of
TABLE II. Meta-analysis of Canadian, American, Australian, German, and Dutch populations for association with PA and food
allergy phenotypes
SNP* Chromosome Allele
PA
P-CanPARya P-CFAb P-HealthNutsyc P-UFAyd
P-IDEAL/GENEVA,
case-controle
P-Dutch GENEVA,
family basedf
rs115218289 2 A/C 1.80 3 1028 NA 6.77 3 1021 NA 7.18 3 1021 3.54 3 1021
rs523865§ 20 C/T 4.42 3 1027 NA NA NA 8.33 3 1021 1.63 3 1022
rs144897250 11 A/C 2.90 3 1027 NA 3.84 3 1021 NA NA NA
rs7936434 11 C/G 5.17 3 1027 3.66 3 1022 1.43 3 1021 NA NA NA
rs78048444§ 7 C/T 5.44 3 1027 NA 2.13 3 1021 NA 6.46 3 1021 3.54 3 1021
rs744597§ 4 A/G 3.983 1027 1.153 1021 5.573 1021 NA 8.203 1022 9.623 1021
rs72827854 17 T/C 2.603 1027 1.363 1021 3.553 1021 NA NA NA
rs55765969 17 T/C 1.233 1026 1.973 1021 2.813 1021 NA NA NA
rs56151068 17 T/C 9.583 1027 2.513 1021 3.573 1021 NA NA NA
rs71193762 10 A/G 3.773 1027 8.633 1021 3.623 1021 NA NA NA
Boldface rows indicate suggestive significance (P <_ 1.493 1026) in patients with PA.
aP value from CanPAR (n5 1,776).
bP value from the Chicago Food Allergy Study (n5 2,197).
cP value from the Australian HealthNuts study (n5 221).
dP value from the German Understanding of Food Allergy study (n5 2,592).
eNumber of subjects5 226, 229, 227, and 217 for rs115218289, rs523865, rs78048444, and rs744597, respectively, corrected for atopic dermatitis, Asthma, and
rhinoconjunctivitis.
fP value from the Dutch GENEVA family study; number of informative families5 20, 112, 21, and 112 for rs115218289, rs523865, rs78048444, and rs744597, respectively.
gP value from the Stouffer weighted z score meta-analysis method for PA.
hP value from the Chicago Food Allergy Study (n5 2,197).
iP value from the Dutch IDEAL and GENEVA case-control studies; number of subjects for SNPs5 479, 487, 482, and 466 for rs115218289, rs523865, rs78048444, and rs744597,
respectively, corrected for atopic dermatitis, Asthma, and rhinoconjunctivitis.
jP value from the Dutch GENEVA study; number of informative families for SNPs5 26, 196, 37, and 214 for rs115218289, rs523865, rs78048444, and rs744597, respectively.
kP value from the GERA food allergy study (n5 29,053).
lP value from the Stouffer weighted z score meta-analysis method for food allergy.
mP value from the Stouffer weighted z score meta-analysis method for food allergy without the GERA cohort.
*SNPs in this table were selected to represent each of the 10 genomic regions identified in the CanPAR GWAS (see Table E4 for full results).
Used for both PA and food allergy (FA).
Imputed SNP from CanPAR.
§Genotyped SNP from CanPAR.
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6 ASAI ET ALsignificance of the other loci in the meta-analysis should be
interpreted with care because there is insufficient power in the
other studies to replicate CanPAR PA findings.
Identification of C11orf30 as a susceptibility locus for food
allergy fits within what is known about this area, as has been
implicated in serum IgE levels35 and asthma.36 Recently,
C11orf30 was identified as a risk factor for eosinophilic
esophagitis (OR, 2.22; P5 5.383 10210),37 a chronic allergic
inflammatory disease of the esophagus that is mainly triggered
by food proteins. Loci in this region have been significantly
associated with atopic dermatitis38 both with (rs2155219)39,40
and without (rs7927894) any other disease-related phenotypes,
such as asthma, allergic rhinoconjunctivitis, total serum IgE level,
or family history of atopy.41 These findings indicate thatC11orf30
is a risk factor for the atopic march, particularly those studies that
investigated childhood eczema with later development of
asthma.38 FLG and HLA-DQB1, genes previously examined in
CanPAR,18,19,22 have similarly been found to be associated with
childhood eczema and asthma.38
It could be argued that the genome-wide significance of
C11orf30 in the food allergy meta-analysis with the addition of
the GERA cohort indicates that the locus represents associationwith an allergic diathesis rather than with food allergy or PA
specifically because of the potential misclassification rate for
self-reported food allergy in the GERA cohort.42 The idea of
C11orf30 being associated with an allergic phenotype is
supported by data that show that C11orf30 is a risk factor for
polysensitization to multiple allergens on skin prick testing.43
C11orf30 is associated with Crohn disease and ulcerative
colitis,44,45 autoimmune inflammatory bowel diseases that are
not classically part of the atopic march, although some
epidemiologic data link eczema with inflammatory bowel
diseases and other autoimmune diseases.46,47 Therefore
C11orf30 could be a risk factor for immune dysfunction disorders
in general.PA, food allergy, or atopy?
The underlying genetic model for PA is unknown: food allergy,
asthma, eczema, and allergic rhinitis can share common genetic
susceptibility, whereas environmental factors determine which
specific atopic disease develops; alternatively, each specific
allergy can have its own risk variants. The genetic model and
study design affect the power to identify risk variants. The
PA Food allergy
Gene/nearest genePmeta_PAg P-CFAh
P-IDEAL/GENEVA,
case-controli P-GENEVA, family studyj P-GERAk Pmetal
Pmeta (without
GERA)m
9.16 3 1028 NA 1.84 3 1021 1.90 3 1021 5.25 3 1021 2.91 3 1022 2.38 3 1028 (298 kb)DLX2j
(26 kb)ITGA6
1.54 3 1027 NA 2.03 3 1021 2.60 3 1022 2.66 3 1021 9.29 3 1023 4.09 3 1028 ANGPT4
2.94 3 1027 NA NA NA 5.89 3 1021 6.83 3 1022 2.94 3 1027 (5 kb)MMP12j
(63 kb)MMP13
3.13 3 1027 5.89 3 1025 NA NA 4.13 3 1024 1.98 3 1028 7.50 3 10211 (30 kb)C11orf30 j
(43 kb) LOC101928813
3.73 3 1027 NA 8.29 3 1021 7.87 3 1021 6.97 3 1021 8.88 3 1022 2.53 3 1026 (65 kb)CHCHD3j
(106 kb)EXOC4
1.633 1026 5.193 1021 1.133 1021 2.693 1021 3.633 1021 1.293 1022 1.423 1025 ARHGAP24
3.433 1026 5.833 1021 NA NA 7.693 1021 9.273 1022 7.473 1025 SKAP1
1.453 1025 6.593 1021 NA NA 3.773 1021 3.183 1022 1.973 1024 LOC101927166
2.333 1025 7.333 1021 NA NA 4.453 1021 4.453 1022 2.663 1024 SKAP1;
LOC101927148
2.733 1024 6.873 1021 NA NA 7.063 1021 8.833 1022 1.413 1024 CTNNA3
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specific for PA, with the use of hyper-control subjects to increase
power, in addition to a defined phenotype for allergy to peanut.
The other food allergy case groups were recruited based on any
food allergy or egg allergy and PA20,21,29; this design might be
more powerful if one assumes that all food allergies are influ-
enced by the same genetic risk loci rather than specific risk loci
for specific foods.Novel pathways in the pathogenesis of food allergy
The identification of C11orf30 as a genetic risk locus for food
allergy opens further research possibilities into the pathways to
food allergy. Mechanistically, it is possible that the C11orf30 re-
gion could be responsible for multiple phenotypes associated with
the atopic march, including food allergy, eczema, and asthma, and
other autoimmune conditions. There are several potential ways
C11orf30 could exert its influence to result in a variety of clinical
presentations and are consistent with an epigenetic connection to
allergic disease.20,48 The protein complex formed by KDM5A, a
histone demethylase, and EMSY, the protein encoded by
C11orf30, appears to increase gene transcription.49 EMSY actsas a reader for trimethylation of lysine 4 on histone protein H3
(H3K4me3)50 through its recruitment with other members of
the EMSY complex to H3K4me3 marked promoters, where it ap-
pears to be positively correlated with transcriptional activity of
target genes and cell proliferation.49
Along with members of the EMSY protein complex, EMSY
colocalizes with CBX1.33 Similar to its highly conserved
Drosophila homolog protein dHP1, CBX1 protein has a binding
affinity for trimethylation of lysine 9 on histone protein H3
(H3K9me3),51 modifications that are linked to transcription
repression.52 In this study CBX1was identified as being regulated
by SKAP1 because the same SNPs that are associatedwith PA also
regulate the gene expression of CBX1, increasing the connections
between the novel loci identified in the CanPAR GWAS. SKAP1,
which has multiple SNPs identified in the CanPAR GWAS, has a
known eQTL in CBX1, which encodes a protein that mediates
gene silencing and alternative splicing,33,34 the product of which
colocalizes with EMSY protein, as encoded by C11orf30.
CTNNA3, also identified as a PA locus in this study, has an iden-
tified copy number variant (CNV;CNVR6828297068284017)53 in
pediatric food allergy. It is also tied to histonemodification because
there is an enrichment of enhancer- and promoter-associated
FIG 2. Quantile-quantile andManhattan plots of related and unrelated analyses conditioned on the top HLA
SNP (rs3134976). A, Quantile-quantile plot of the expected distribution of test statistics (x-axis) versus
observed P values (y-axis) for related analysis conditioned on rs3134976. SNPs in complete linkage with
rs3134976 were excluded. B,Manhattan plot: SNPs in 850 patients with PA and 926 hyper-control subjects
for the related analysis conditioned on rs3134976. The x-axis denotes genomic location, and the y-axis
denotes association level. The solid line indicates the threshold for genome-wide significance
(P <_ 3.603 1028), and the dashed line indicates the suggestive association significance threshold
(P <_ 1.493 1026).
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protein 3) in CTNNA3 CNVR.53
Identification of multiple genes (C11orf30, SKAP1, and
CTNNA3) involved with histone-related proteins supports the
hypothesis that epigenetic regulation is mechanistic in the
development of allergy. Early exposure to peanut prevents
development of PA,7 and maintenance of peanut consumption
promotes continued tolerance of peanut8; the identified themeof histone-related loci reveals a potential biological mechanism
through which this epigenetic phenomenon can occur. This
finding could pave the way for potential therapies for those
already affected by PA.
Several SNPs in or near genes related to vascular and
endothelial cell factors were identified in this study and could
be involved in the pathophysiology of PA and food allergy
through 2 putative mechanisms: (1) an endothelial barrier defect
TABLE III. Top CanPAR SNPs associated with PA and eQTLs for each locus and tissue type
SNP Chromosome Position Nearest gene Tissue P value Gene symbol
rs4491576 17 46,408,636 SKAP1 Whole blood 1.053 10210 SNX11
rs16956501 17 46,497,274 SKAP1 Skin, sun-exposed lower leg 4.483 10210 SNX11
rs139462954 17 46,523,678 LOC101927166 Skin, sun-exposed lower leg 8.943 10210 SNX11
rs139462954 17 46,523,678 LOC101927166 Cells, transformed fibroblasts 7.363 1027 CBX1
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antigen-presenting cells. Some evidence suggests that lymphatic
endothelial cells present self-antigens and help regulate periph-
eral T-cell tolerance.54 Several identified loci from this study have
connections to both allergy and vascular regulation (CTNNA3),55
permeability (ANGPT4),56,57 or endothelial cell function
(SKAP158 and EXOC459). Their true role in the pathogenesis of
allergic disease requires further research.Strengths and limitations of the study
Many of the strengths of this study are directly tied to its
limitations. The CanPAR study is large, with 850 cases after QC,
and is the largest of the included case groups by a factor of 3,
although it is still small for a GWAS. There are no similar PA case
groups of equivalent size; this complicates the replication of novel
hits. The 6 studies included in the meta-analysis only contribute
an additional 732 patients with PA, which results in insufficient
power to replicate CanPAR findings.
There are numerous sources of heterogeneity that increase the
variance of effect size estimation and reduce power. These
include study design, ascertainment criteria, case and control
phenotype definition, ethnicity, age, and small sample size.
Differences in ascertainment criteria (food allergy vs PA) can
result in differences in the power of the studies to identify
susceptibility genes for PA versus food allergy, even in the
presence of equivalent sample sizes. The effect of ascertainment
criteria on the power ultimately depends on the underlying
genetic model and will differentially affect loci with peanut-
specific susceptibility. The Dutch IMPACT and GENEVA
samples are small and contribute point estimates for only 4
SNPs that were specifically genotyped for this study; the absence
of genome-wide association data precludes the use of principal
components to control for population stratification when gener-
ating the point estimates for the IMPACT and GENEVA studies.
The importance of phenotyping food allergy is evident by the
sizable changes in P values when a large cohort of self-reported
GERA cohort subjects with food allergy was added to the
meta-analysis, which highlights the potential difference in
mechanism for C11orf30. The prevalence of food allergy in the
GERA cohort, which is self-reported with no corroborating
clinical history or diagnostic tests, is 17.58%, which is much
higher than other population-based studies in North America
(6.4% to 7.5%),2 indicating there is likely a high case
misclassification rate. Misclassification is a known differential
bias to the null and can result in false-negative results, which
can be problematic for relatively rare phenotypes, such as PA
and food allergy, because the misclassification rate can exceed
the disease prevalence rate. This is particularly an issue in the
use of universal controls, where genotyping of control subjects
has been performed in a separate experiment and misclassifica-
tion of cases and control subjects is common. Misclassification
of an affected subject as a control subject is much less costlythanmisclassification of a control subject as an affected subject.60
A strength of the CanPAR study is that the cases and control
subjects were genotyped in the same experiment. Additionally,
using hyper-control subjects with a comprehensive longitudinal
lifetime history and in-depth phenotyping of asthma, atopy, skin
prick tests, IgE, airway hyperresponsiveness, and eczema
phenotypes virtually eliminates misclassification of control sub-
jects in the CanPAR study.
Careful consideration of potential misclassification needs to be
made when using self-reported food allergy phenotypes in the
absence of food challenges, skin prick tests, and food-specific IgE
measurements. This has important implications in today’s
research environment, where investigators are continually
striving to maximize the use of existing GWAS data. We also
see this conundrum with the common adoption of general
population controls, which might contribute to population
stratification and can result in false-positive results, a differential
bias away from the null; both the CanPAR and UFA studies used
this approach. The use of hyper-control subjects in the CanPAR
study increased the power to detect associations with PA butmade
evaluation of confounders, such as eczema or asthma, difficult
because none of the control subjects expressed these phenotypes.
Use of this study design with control subjects from a different
population limits our ability to evaluate early-life environmental
exposures.
Direct genotyping was not conducted for rs7936434 (imputed),
the most significant association observed in the C11orf30/EMSY
region. Although direct genotyping would ensure that the finding
is not an imputation artifact, it is unlikely that the observed asso-
ciation is due to an artifact. The C11orf30/EMSY locus reached
genome-wide significance because of the contributions not only
of the CanPAR study but also 2 other studies (CFA study and
GERA cohort). Additionally, the strong correlation of this locus
with allergy and atopic conditions in multiple studies35-41 serves
to alleviate concerns that this association might be an imputation
artifact.
Despite all limitations, this study robustly identified new loci
for PA and food allergy with genome-wide significance
(P5 7.503 10211) across populations in a meta-analysis of
unprecedented size (1,582 patients with PA and 5,446 control
subjects and 7,627 patients with food allergy and 29,084 food
allergy control subjects). It is important to note the effect sizes
for the loci identified are large, particularly for a complex disease,
and that the finding of C11orf30/EMSY is robust because it
demonstrates association across the studies, despite study
diversity. eQTL data support these new loci and suggest new
pathways in the pathogenesis of food allergy.Conclusion and future directions
The results of this study identify novel genetic risk factors for
PA and food allergy. New pathways identified by using this
J ALLERGY CLIN IMMUNOL
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and those with food allergy and the importance of epigenetic
mechanisms. It is evident that further work will require larger
sample sizes and international collaboration by using
well-phenotyped subjects for both food allergies and other atopic
conditions. Functional work, including studies of vascular and
endothelial cell factors, might be valuable. Future studies will
need to examine gene-environment interactions, including
duration, timing, and mode of environmental exposure and the
role of CNVs, methylation, and histone modification.
We thank the subjects and parents who participated in this study and in the
CanPAR registry and their allergists for help in diagnostic documentation. We
appreciate the help with subject recruitment from our partners: Food
Allergy Canada (formerly Anaphylaxis Canada), Allergies Quebec (formerly
l’Association Quebecois des Allergies Alimentaires), and the Allergy/Asthma
Information Association. We acknowledge Basia Rogula and David Yin, who
assisted in quality control; JinCheol Choi, who assisted with figure
development; and Jessica Que, who assisted with SNP annotation. Whitney
Steber, Chynace Van Lambalgen, HeatherWaldhauser, Greg Shand, Elizabeth
Turnbull, and Popi Panaritis assisted in data/DNA collection for CanPAR. We
thank Peter Pare for his valuable comments and Reza Alizadehfar, Edmund
Chan, and Peter Hull for their data collection and helpful discussions. The data
used for the analyses described in this article were obtained from the GTEx
Portal on January 1, 2017, to February 28, 2017.
Key messages
d The C11orf30 (EMSY) locus is a novel genetic risk
factor for both PA and food allergy, reaching genome-
wide significance for food allergy in a meta-analysis
(P5 7.503 10211).
d New loci associated with ANGPT4, MMP12/MMP13, and
EXOC4 are suggestive of association with PA and food
allergy.
d Epigenetic mechanisms might be a new pathway in the
pathogenesis of PA.REFERENCES
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